Singapore, Oct. 17 -- Germany's Boehringer Ingelheim and Korean biotech startup AimedBio have announced a global collaboration and licensing agreement to develop a novel antibody-drug conjugate (ADC) therapy for a broad range of cancers. The agreement further strengthens Boehringer's growing ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company's aim of transforming the lives of people with cancer.

ADCs harness the specificity of monoclonal antibodies and the potency of cytotoxic agents - in this case a derivative of exatecan - to selectively target and eliminate cancer cells while minimising damage to healthy tissue. The ADC developed by AimedBio targets a protein that is highly expressed across a broad spect...